# Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis

> **NCT07256184** · — · COMPLETED · sponsor: **Ankara Etlik City Hospital** · enrollment: 232 (actual)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **DRUG:** Systemic Therapy for Metastatic Melanoma

## Key facts

- **NCT ID:** NCT07256184
- **Lead sponsor:** Ankara Etlik City Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-12-15
- **Final completion:** 2024-12-15
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07256184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07256184, "Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT07256184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*